CN116916924B - Malt1调节剂及其用途 - Google Patents

Malt1调节剂及其用途

Info

Publication number
CN116916924B
CN116916924B CN202180083881.6A CN202180083881A CN116916924B CN 116916924 B CN116916924 B CN 116916924B CN 202180083881 A CN202180083881 A CN 202180083881A CN 116916924 B CN116916924 B CN 116916924B
Authority
CN
China
Prior art keywords
alkyl
trifluoroethyl
triazolo
chloro
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180083881.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN116916924A (zh
Inventor
B·A·德克里斯托弗
G·巴布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rare Bioscience Co ltd
Original Assignee
Rare Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rare Bioscience Co ltd filed Critical Rare Bioscience Co ltd
Publication of CN116916924A publication Critical patent/CN116916924A/zh
Application granted granted Critical
Publication of CN116916924B publication Critical patent/CN116916924B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Escalators And Moving Walkways (AREA)
  • Inspection Of Paper Currency And Valuable Securities (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
CN202180083881.6A 2020-10-16 2021-10-15 Malt1调节剂及其用途 Active CN116916924B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092768P 2020-10-16 2020-10-16
US63/092,768 2020-10-16
PCT/US2021/055173 WO2022081967A1 (en) 2020-10-16 2021-10-15 Malt1 modulators and uses thereof

Publications (2)

Publication Number Publication Date
CN116916924A CN116916924A (zh) 2023-10-20
CN116916924B true CN116916924B (zh) 2026-02-27

Family

ID=81209361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180083881.6A Active CN116916924B (zh) 2020-10-16 2021-10-15 Malt1调节剂及其用途

Country Status (7)

Country Link
US (1) US20230391781A1 (https=)
EP (1) EP4228647A4 (https=)
JP (1) JP7818011B2 (https=)
CN (1) CN116916924B (https=)
AU (1) AU2021361057A1 (https=)
CA (1) CA3198715A1 (https=)
WO (1) WO2022081967A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
EP4638458A1 (en) * 2022-12-23 2025-10-29 Janssen Pharmaceutica NV Malt1 inhibitors
WO2024182599A2 (en) * 2023-03-01 2024-09-06 Rarefied Biosciences, Inc. Compositions and methods for treating malt1 associated diseases
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214136A (zh) * 2016-12-21 2019-09-06 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
CN110312724A (zh) * 2016-07-29 2019-10-08 陆品有限公司 作为malt1抑制剂的取代的噻唑并-吡啶化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5593996A (en) * 1991-12-30 1997-01-14 American Cyanamid Company Triazolopyrimidine derivatives
EP1644003A1 (en) * 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
WO2008065198A1 (en) * 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
SG11201607895PA (en) * 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
US10711036B2 (en) * 2015-08-28 2020-07-14 Cornell University MALT1 inhibitors and uses thereof
EP3810609B1 (en) 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
TWI848400B (zh) * 2018-11-28 2024-07-11 日商武田藥品工業股份有限公司 雜環化合物及醫藥

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312724A (zh) * 2016-07-29 2019-10-08 陆品有限公司 作为malt1抑制剂的取代的噻唑并-吡啶化合物
CN110214136A (zh) * 2016-12-21 2019-09-06 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物

Also Published As

Publication number Publication date
EP4228647A4 (en) 2024-09-11
EP4228647A1 (en) 2023-08-23
CA3198715A1 (en) 2022-04-21
AU2021361057A1 (en) 2023-06-08
AU2021361057A9 (en) 2025-03-20
JP7818011B2 (ja) 2026-02-19
CN116916924A (zh) 2023-10-20
US20230391781A1 (en) 2023-12-07
WO2022081967A1 (en) 2022-04-21
JP2023552002A (ja) 2023-12-13

Similar Documents

Publication Publication Date Title
CN116916924B (zh) Malt1调节剂及其用途
AU2021273566B2 (en) Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
EP3761980B1 (en) Amino acid compounds and methods of use
WO2021225912A1 (en) Treatment of respiratory diseases with amino acid compounds
WO2022081995A1 (en) Malt1 modulators and uses thereof
AU2020405536B2 (en) Benzimidazole derivatives
CA3116830A1 (en) Heteroaromatic compounds as vanin inhibitors
WO2004098520A2 (en) Compounds and compositions as protein kinase inhibitors
AU2005262330A1 (en) Piperidine derivatives as NK1 antagonists
EP3946606A1 (en) Bicyclic jak inhibitors and uses thereof
RU2761626C2 (ru) ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
EP4499611B1 (en) Malt1 modulators and uses thereof
WO2020033709A1 (en) Inhibiting deubiquitinase usp25 and usp28
RU2803284C1 (ru) Производные бензимидазола
WO2024041397A1 (en) Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
HK40106342A (en) Amino acid compounds and methods of use
TW202411214A (zh) 治療性化合物
EA045845B1 (ru) Противовирусные средства для лечения и профилактики вич-инфекции
OA20759A (en) Benzimidazole derivatives.
HK1262463A1 (en) Heterocycles useful as anti-cancer agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant